AGP Executive Report
Last update: 8 hours agoCBD & Anxiety Research: A new explainer revisits what the evidence says about cannabidiol for anxiety, noting promising signals since 2020 but also clear limits in how lab findings translate to real-world treatment. Public Health Warning (CHS): The CDC reports 199,565 emergency visits tied to cannabis hyperemesis syndrome from Jan. 2023–May 2026, with a jump after a dedicated diagnostic code in Oct. 2025 improved detection. Pregnancy Safety: A Nature study using a new placental atlas links cannabis use during pregnancy to higher-risk placental cell patterns, adding more urgency to clinician guidance. California Enforcement: Gov. Newsom highlights results from removing illegal hemp, kratom and 7-OH products from shelves, citing high compliance rates plus thousands of removals. Hemp THC Policy: The U.S. House passed a stopgap funding bill that delays a federal ban on intoxicating hemp THC products until Dec. 11, keeping the industry’s near-term future in play. Industry/Markets: Vireo Growth announced it will attend an investor conference in NYC on Sept. 9.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
